A
Ana Cristina Gallego-Hernández
Publications - 7
Citations - 149
Ana Cristina Gallego-Hernández is an academic researcher. The author has contributed to research in topics: Biology & Neutralization. The author has an hindex of 5, co-authored 7 publications receiving 149 citations. Previous affiliations of Ana Cristina Gallego-Hernández include Vaccine Research Institute.
Papers
More filters
Journal ArticleDOI
The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation.
Maaran Michael Rajah,Maaran Michael Rajah,Ana Cristina Gallego-Hernández,Annie Bernier,Julian Buchrieser,Olivier Schwartz,Olivier Schwartz +6 more
TL;DR: In this article, the authors discuss the molecular determinants of S mediated fusion and the antiviral innate immunity components that counteract syncytia formation in SARS-CoV-2 infection and pathology.
Journal ArticleDOI
The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation
TL;DR: In this paper , the authors discuss the molecular determinants of S mediated fusion and the antiviral innate immunity components that counteract syncytia formation in SARS-CoV-2 infection and pathology.
Posted ContentDOI
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies
TL;DR: In this paper , the authors established a viral amplification procedure to easily isolate SARS-CoV-2 Omicron strains, including BA.2, BA.1.4 and BA.75.2.
Posted ContentDOI
Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without Omicron breakthrough infection
TL;DR: In this paper , the authors evaluated the duration of the neutralizing antibody (Nab) response, up to 16 months after Pfizer BNT162b2 vaccination, in individuals with or without BA.1/BA.2 breakthrough infection.
Posted ContentDOI
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 in patients receiving monoclonal antibodies
TL;DR: In this paper , the authors evaluated the neutralization and ADCC activity of 6 therapeutic mAbs against Delta, BA.4 and BA.5 isolates and found that Sotrovimab was the most efficient at eliciting ADCC.